Overview
Dr. Gulick is Principal Investigator of the Cornell Clinical Trials Unit of the National Institutes of Health-funded AIDS Clinical Trials Group (ACTG). His current research focuses on clinical trials of antiretroviral therapy for the treatment and prevention of HIV infection.
Highlights
- 1
- 2Journal of acquired immune deficiency syndromes (1999) · 2021
- 3AIDS and behavior · 2024
Publications
Funding
Active
8 grants- Sub-PIP30AI191337-01A1Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
- MPIT32AI007613-27Research Training in Infectious DiseasesNational Institute of Allergy and Infectious Diseases · 2014–2030· 3 renewals
- Co-I1 TR7HA53197-01-00Northeast/ Caribbean AIDS Education and Training Centers - MAIHealth Resources and Services Administration · 2024–2029 · via Columbia University
- PIUM1AI069419-20Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitNational Institute of Allergy and Infectious Diseases · 2013–2027· 4 renewals
- MPIUM1AI068636-18ACTG LOC: PF A5391 – Y2 Protocol co-Chair (1560)National Institute of Allergy and Infectious Diseases · 2011–2027 · via University of California, Los Angeles· 9 renewals
- Co-IUM1CA121947-15AMC Domestic Site - Weill Cornell MedicineNational Cancer Institute · 2020–2026 · via EMMES Corporation
- Sub-PI3001170169HIV Prevention Trials Network (HPTN 083 FHI360 - WCM)ViiV Healthcare UK Limited · 2017–2025 · via FHI 360
- MPIUM1AI068619-17HIV Prevention Trials Network (HPTN 083 FHI360 - WCM)National Institute of Allergy and Infectious Diseases · 2011–2025 · via FHI 360· 9 renewals
Completed grants (11)
- Sub-PIFHI 192122-03HPTN 083 - Viiv FundingViiV Healthcare UK Limited · 2018–2025 · via FHI 360
- KPM38-CO-065-0910-4INSIGHT Flu002: An International Observational Study to Characterize Adults with InfluenzaNational Institute of Allergy and Infectious Diseases · 2009–2024 · via Institute for Clinical Research
- Co-I20-WCORNELL-01Ending the HIV Epidemic (Collaboration for CME Accreditation (AETC))Health Resources and Services Administration · 2020–2021 · via Public Health Solutions
- PIFHI 204681-01HPTN Studies PPE - FHI FundingFHI 360 · 2020–2021
- KP5 U1O HA29291-02AIDS Education and Training Centers Program (AETC)Health Resources and Services Administration · 2015–2019 · via Columbia University
- KPM38-CO-065-0910-4INSIGHT 001: Strategic Timing of AntiRetroviral Treatment (START)National Institute of Allergy and Infectious Diseases · 2010–2019 · via Institute for Clinical Research
- PISA 183489-01Consulting agreement for Daniel FiererNational Institutes of Health · 2018–2019Contract
- MPIU01AI118536-033BNC117 mAb in HIV-Infected Subjects on Combination ARTNational Institute of Allergy and Infectious Diseases · 2015–2018 · via Rockefeller University
- Sub-PIOPP1092074 (ClinicalPassive Immunotherapy With Human Anti-HIV Neutralizing Monoclonal Antibodies (3BNC117) - Supplement To OPP1092074Bill & Melinda Gates Foundation · 2014–2017 · via Rockefeller University
- PIK24AI051966-10Antiretroviral Therapy for HIV-Infected PatientsNIAID · 2003–2013 · via NIH RePORTER
- MPIM01RR000047-47A5175: A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACNCRR · 2004–2007 · via NIH RePORTER
Honors & distinctions
- Member · American Society for Clinical Investigation · 2006
- Member · Association of American Physicians
Clinical research
Completed & closed trials (2)
- PINCT00031408Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified AnalysesNational Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)HIV Infections
- PINCT04636437Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)PHASE4 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)HIV Infections
News mentions
- Omicron: What We Know So FarDecember 7, 2021
Omicron — the latest coronavirus variant to be labeled a “variant of concern” — has been spreading rapidly in the United States and dozens of countries around the world.
- Booster Shots: What You Need to KnowSeptember 16, 2021
In a Q&A, Dr. Roy Gulick breaks down the science underlying COVID-19 booster shots and answers some frequently asked questions about the vaccines.
- The Delta Variant: What You Need to KnowJuly 8, 2021
The spread of the Delta variant has put countries around the world on high alert. Dr. Roy M. Gulick, chief of the Division of Infectious Diseases at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, and professor of medicine at Weill Cornell Medicine, answers questions about the new threat.
- Weill Cornell Medicine Physicians Author Guide to Management of Severe COVID-19June 5, 2020
Critical care physicians, infectious disease specialists and pulmonologists from Weill Cornell Medicine and NewYork-Presbyterian have published a clinical practice guide for managing severe COVID-19 in the New England Journal of Medicine.
- Awards and Honors Across Weill Cornell Medicine - April 30, 2020April 30, 2020
Awards, honors, prizes and achievements for the month of April.
Media highlights
- Flu Arrives Early In New York, With Cases Rising Rapidly In ChildrenThe New York Times · November 2, 2026
- Dangerous Rabid Beavers Attack 2 Teens, With 1 Airlifted And Popular Park Partially ClosedFox News · August 17, 2026Also in New York Post
External relationships
Advisory/Scientific Board Member
Ashfield Healthcare · George Washington University, The · UpToDate, Inc.
Other Interest
Ashfield Healthcare · International Antiviral Society-USA